Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.45% | -11.62% | -23.65% | -32.78% | -22.12% |
| Total Depreciation and Amortization | 6.93% | 5.62% | 6.67% | 9.62% | 8.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.23% | 4.76% | 3.00% | 10.87% | 98.93% |
| Change in Net Operating Assets | -542.31% | -260.46% | -380.79% | 146.03% | 422.89% |
| Cash from Operations | -43.69% | -47.06% | -63.53% | -7.78% | -10.76% |
| Capital Expenditure | -16.68% | -5.56% | -31.87% | 8.51% | 14.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.80% | -177.22% | -593.48% | -574.81% | -452.49% |
| Cash from Investing | 114.37% | -174.27% | -602.46% | -582.76% | -458.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.15% | 102.07% | 26,460.59% | 14,419.77% | 14,541.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.15% | 102.07% | 26,460.59% | 14,419.77% | 14,541.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -260.68% | -219.93% | 498.39% | 8,300.56% | 111.43% |